Latest news with #MSC
Time of India
a day ago
- General
- Time of India
No significant pollution or environmental damage caused by MSC ELSA 3 capsize so far: Shipping company
Kochi: Mediterranean Shipping Company (MSC), owner of the cargo vessel MSC ELSA 3, which capsized off Kerala coast on May 25, has informed high court that no significant pollution or environmental damage has been caused by the incident so far. Tired of too many ads? go ad free now According to MSC, the light oil sheen initially observed around the vessel's location was promptly contained, and it has since dispersed. All accessible vents and sounding pipes from which oil could potentially escape have been capped. Therefore, at present, there is no imminent threat of an oil spill, environmental damage, or any related consequences. These submissions were in response to petitions filed by former MP T N Prathapan and others, seeking comprehensive compensation and rehabilitation for fishermen and other stakeholders affected by the incident. The affidavit filed by MSC further states that of the 643 containers on board, 13 contained legally permitted hazardous cargo. It is believed that all 13 containers sank with the vessel. None of the 61 containers retrieved so far contained hazardous material. The other cargo on board included plastic products known as nurdles, of which more than 70 tonnes have been collected by special teams. MSC also informed that the removal of fuel from the vessel's bunker tanks requires saturation diving — a high-risk operation unfeasible under the current weather conditions. Also, the wreck does not appear to pose any navigational hazard and does not obstruct fishing activities. The vessel is currently stable and resting on the seabed at a depth of 54.5 meters. HC will consider the petitions on Wednesday. The affidavit also describes the events leading to the shipwreck, stating that at 1am on May 24, the vessel developed a concerning starboard list, which continued to increase despite efforts by the crew to correct it. At that time, the vessel was approximately 38 nautical miles southwest of Kochi and 21.5 nautical miles from the nearest Kerala coast. By 3.15am, the list had increased to 30 degrees. The crew still onboard took proactive steps to stabilise the vessel, and about 40 containers fell overboard, reducing the list to 20-22 degrees. However, the crew members were subsequently evacuated following a directive from DG Shipping, and although further efforts were made to correct the list, they were ultimately unsuccessful.
Time of India
a day ago
- Business
- Time of India
Shipwreck off Kerala coast: Plea seeks arrest of ship against $134-million damage claim
Kochi: A petition has been filed in high court seeking a directive to arrest any vessel of the Mediterranean Shipping Company (MSC) currently within Indian admiralty jurisdiction, to secure a maritime claim of $134 million for the damage caused by the capsizing of the cargo vessel MSC ELSA 3 off Kerala coast. The public interest litigation (PIL) filed by Charles George, president of Kerala Fish Workers Coordination Committee and Swatantra Matsya Thozhilali Union, has been adjourned to Wednesday by the bench of Chief Justice Nitin Jamdar and Justice Basant Balaji for consideration along with related petitions. The Liberian-flagged MSC ELSA 3 sank approximately 14.6 nautical miles off Alappuzha coast on May 25. The petitioner submitted that the incident has triggered catastrophic ecological, economic and legal consequences. The continued presence of hazardous containers and bunker oil poses severe risks to Kerala's marine biodiversity, particularly during the monsoon fish spawning season protected under the trawling ban. Oil sardines, a vital source of income for Kerala's coastal fishermen, are at risk of extinction due to this maritime disaster. He also prayed for a directive to MSC to initiate and complete urgent wreck removal operations of the sunken vessel MSC ELSA 3 in a strict time-bound manner. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo The petition further sought a directive to the shipping company to deposit an amount of $134 million with the high court registry as security for future compensation to be awarded to the affected stakeholders, including the local fishing community, environmental agencies and state govt, in proportion to the environmental and economic damage caused by the incident. Get the latest lifestyle updates on Times of India, along with Doctor's Day 2025 , messages and quotes!
Yahoo
3 days ago
- Business
- Yahoo
Kalmar and AGL collaborate on STS crane repair and refurbishment project in Abidjan
STS crane repair and refurbishment project in Abidjan STS crane repair and refurbishment project in Abidjan KALMAR CORPORATION, TRADE PRESS RELEASE, 30 JUNE 2025 AT 10 AM (EEST) Kalmar and AGL collaborate on STS crane repair and refurbishment project in Abidjan Kalmar and Africa Global Logistics (AGL) have cooperated on a project to refurbish two ship-to-shore (STS) cranes at AGL's container terminal in the Port of Abidjan, Ivory Coast. The project was delivered as part of Kalmar's Modernisation Services offering. The order was booked in Kalmar's Q4 2024 order intake, and the work was completed during Q1 2025. AGL, part of MSC, employs over 20,000 people across 50 countries and is a major player in the port logistics sector in Africa. The company operates 17 container terminals, seven RoRo/ConRo terminals and one inland port terminal and invests in port infrastructure to serve shipowners, import and export customers and the countries in which it operates. AGL's equipment fleet includes Kalmar reachstackers and forklifts. Kalmar has successfully completed several similar repair and refurbishment projects for AGL's crane fleet, including on units operating at the company's terminals in Congo and Benin. The project scope for the cranes in Abidjan included replacement of the cranes' forestay and pivot point bearings, trolley rails, short rails and trolley and guide wheels. Kehinde Salami, Deputy Technical Director, HQ Technical Department, AGL: 'We have collaborated with Kalmar on several crane repair and refurbishment projects in the past, all of which have been completed on time and to the highest standards of quality. It was therefore a natural step to work with them again on the project at Abidjan. The work done by Kalmar will help to keep our STS cranes operating safely and reliably.' Peter Bos, Project Manager, Kalmar: 'We are proud that AGL chose to rely on our deep crane repair and refurbishment expertise for this latest project in Abidjan. In addition to the repair and refurbishment work, we also delivered a comprehensive maintenance training programme for the team of port technicians at Abidjan that will help them ensure the cranes remain in optimal condition far into the future.' Further information for the press: Thomas Malmborg, President, Services, Jenni Laukkonen, Director, Marketing and Communications, Kalmar Services, tel. +358 40 8322 331, Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in sustainable material handling equipment and services. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,200 people. In 2024, the company's sales totalled approximately EUR 1.7 billion. Attachments STS crane repair and refurbishment project in Abidjan STS crane repair and refurbishment project in Abidjan
Hindustan Times
6 days ago
- Politics
- Hindustan Times
Haryana: Water supply cut, told to leave hostels: Hisar agri varsity students
Jun 27, 2025 10:06 AM IST Tensions escalated at Chaudhary Charan Singh Haryana Agricultural University, Hisar, on Thursday as protesting students and varsity authorities remained at loggerheads. The authorities reportedly cut water supplies and asked students to vacate their hostels after the semester exams ended. The students of Chaudhary Charan Singh Haryana Agricultural University protest on a road in Hisar on Thursday. (HT Photo) Female postgraduate students claimed they were denied food and told to leave. Additional warden Nidhi Kamboj posted on WhatsApp, 'Postgraduate students who have permission for staying in summer break are allowed to stay otherwise no one will be allowed.' Undergraduates were directed to fetch luggage tonight. The mess remains closed, with nightpass requests directed to the warden. Agitated students began cooking at the protest site and vowed a long-haul sit-in 'until the government gives us written acceptance of our eight demands,' said BSc student Deepanshu. They threatened to shut down the varsity from July 2 if their demands—negotiated with a government panel—aren't formally accepted. MSC girls additionally alleged they were marked as failed online, despite assurances from the panel that exams would be reconducted after three weeks. 'The government is using various tactics to suppress our voices,' they claimed. Student leader Rohit Dalal alleged VC Prof B R Kamboj refused to honour minister Mahipal Dhanda's commitment and blamed students for the ongoing stalemate. Meanwhile, a varsity spokesperson maintained that vacating hostels after semester-end was a routine practice.
West Australian
6 days ago
- Health
- West Australian
New dawn for NeuroScientific with stem cell acquisition
Stem cell therapies have long promised to press the body's reset button - potentially reversing injuries and damage from disease, regenerating tissue and reshaping modern medicine. For ASX-listed NeuroScientific Biopharmaceuticals, that promise starts now thanks to its $5.1 million acquisition of unlisted Perth-based stem cell therapy company Isopogen. The deal will hand NeuroScientific the keys to Isopogen's patented 'StemSmart' technology, which innovatively prepares a specific type of stem cell, mesenchymal stem cells (MSC), for use as an intravenous infusion. MSC are universal donor cells, meaning that there is no need for matching between a donor and recipient. The are effectively an 'off-the shelf' cell therapy. Over the past 20 years, haematology medical scientist Dr Marian Sturm, NeuroScientific's incoming chief scientific officer, pioneered the development of MSCs in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre. The cells have so far been used in many patients, including as a last-line treatment for critically ill patients suffering severe immune complications from bone marrow transplantation and in kidney and lung transplant rejection, through early phase clinical trials and studies and on compassionate grounds, with promising results. The MSC technology has also been employed to treat patients with severe Crohn's disease, an inflammatory autoimmune condition that affects the gut. The disease can develop into very difficult-to-manage and treat forms, including refractory Crohn's, in which patients experience persistent uncontrolled flare-ups, and fistulising Crohn's, in which patients develop an open wound from a gut flare-up out to the skin. In a phase two trial targeting refractory Crohn's disease, a condition that no longer responds to standard treatments, of 18 patients treated with StemSmart MSC, 78 per cent of patients experienced clinical improvement and 44 per cent achieved full remission. That level of efficacy is considered impressive in the MSC field, particularly for refractory Crohn's. With the global market for refractory Crohn's treatment alone estimated to be worth about US$7.5 billion, it's no wonder StemSmart's new owner quickly hailed the system as a potential game-changer. StemSmart technology offers a step up from traditional MSC manufacturing in that the cells are grown in a special media, becoming activated in the process. The platform technology was developed at Royal Perth Hospital (RPH) and manufactured using RPH's processes. Notably, the manufacturing methodology can yield more than 200 cryopreserved clinical doses from just 10 millilitres of precious donated bone marrow, giving it both clinical flexibility and manufacturing scale. Based on the early results in Crohn's disease and in other conditions, Sturm now sees hope in employing MSCs to treat other autoimmune and inflammatory diseases, possibly including lupus, multiple sclerosis and rheumatoid arthritis. As the cells can grow into skin, bone, fat and other tissue cells, they also offer potential applications for tissue repair, such as bone repair for skull or long bone injuries, for example. The clinical development of MSC stretches back to 2002, when a Swedish paediatric haematologist used MSCs for the first time to treat a child gravely ill with complications from the treatment of leukaemia. The cells were isolated and grown in the doctor's laboratory from bone marrow donated by the child's mother. The child's clinical response to the cells was striking. No doubt, the successful experimental treatment would have caught the attention of immunology and haematology researchers and clinicians worldwide, including Sturm, an expert in blood, cell and tissue transplant manufacturing for clinical applications, who was the then-director of RPH's cutting-edge Cell and Tissue Therapy facility. At the time, Sturm was particularly focused on delivering MSCs as safely as possible into healthcare areas of unmet need. She began experimenting with ways to process the cells into a safe infusion that could be used to treat diseases and transplant complications where there were few or no existing clinical options. In 2007, Dr Sturm was approached by her clinical colleagues, who wanted to use the MSC product on compassionate grounds to treat a critically ill man with complications of bone marrow transplant to treat blood cancer. At the time, about 60 per cent of bone marrow transplant patients, who received donor marrow, developed a serious complication, known as graft-versus-host disease (GVHD), where the new blood system created by the bone marrow transplant rejects the recipient's body. It usually presents with symptoms that affect the gut, skin and liver, and is treated with steroids. With recent advancements in transplant practices, the incidence of acute GVHD has fallen to now occurring in about 25-30 per cent of cases. However, these medicines fail in about 30 per cent of acute GVHD cases – and most of this group die. After receiving MSC treatment, the man quickly recovered, spurring Sturm to keep working to develop a scalable, commercial-grade MSC product and patenting the manufacturing process. After an agreement was reached between Isopogen and the State Government's East Metropolitan Health Service (EMHS) giving Isopogen control of the MSC technology, NeuroScientific struck a deal with Isopogen to progress StemSmart. The all-scrip acquisition sees Isopogen shareholders receive 85.7 million NeuroScientific shares and 57.1 million performance shares tied to future clinical and commercial milestones. The market welcomed the move, with NeuroScientific's share price surging 97 per cent on the day of the announcement. A $3.5 million capital raise led by Perth corporate advisor Westar Capital, after existing funds, creates a war chest of about $7.5 million. This will support further development, including for a special access program or bigger phase 2/3 trials for patients with refractory and fistulising Crohn's, and will enable regulatory engagement with Australia's Therapeutic Goods Administration with a long-term goal of partial or full registration for StemSmart MSC, first up as a Crohn's treatment. The company is also eyeing the United States, where inflammatory bowel disease is forecast to grow into a lucrative US$13.8 billion market by 2026. About 30 per cent of Crohn's patients fail to respond to current gold-standard treatments, such as biologics, making them prime candidates for a new approach, such as StemSmart. The takeover signals a bold pivot for NeuroScientific, which previously focused on peptide-based drugs for neurodegenerative diseases such as Alzheimer's. Those drugs showed promise, but the timelines to market were long. By contrast, StemSmart's progress and results over decades of development position the product closer to near-term commercialisation, helped along by NeuroScientific's healthy bank balance. Nor will NeuroScientific be walking away from its roots completely. Two current directors will remain on the company's revamped board, and management will explore crossover applications for StemSmart, particularly to tackle the neuroinflammation that is a hallmark of inflammatory diseases such as Alzheimer's. That convergence could open a dual-front therapeutic pipeline, leveraging both peptide and cellular approaches. While competition in the stem cell space is fierce, the upside is enormous. Importantly, the US Food and Drug Administration (FDA) recently approved the first mesenchymal stromal cell therapy by ASX-listed, regenerative medicine company Mesoblast. While MSC products have been approved in other jurisdictions, the FDA approval of an allogeneic, bone marrow-derived MSC product for paediatric, steroid-refractory, acute graft-versus-host disease is momentous. According to NeuroScientific, StemSmart is differentiated by its purity, potency and consistency. In preclinical and early human data, the platform has shown enhanced potency over conventional MSCs. The recent regulatory FDA approval of MSC also tilt the momentum in StemSmart's favour, suggesting regulators are warming to well-characterised stem cell platforms with rigorous clinical data. Is your ASX-listed company doing something interesting? Contact:
